A group from Department of Thoracic Surgery, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, etc. has reported that KLF12/Gal-1 axis may serve as a novel cancer therapeutic target for patients with immunotherapy resistance.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10432659/
In this study, it was demonstrated that the decline in KLF12 in tumor cells is an important mechanism for immune escape, leading to resistance to anti-PD-1 therapy. Mechanistically, KLF12 could directly bind to the promoter region of Gal-1 and inhibit its expression, and thereby promotes CD8+ T cell infiltration into the tumor microenvironment and kills tumore cells.
Continued research into the mechanisms of action of KLF12 and a new combination immunotherapy for circumventing drug resistance may provide more effective treatment options for patients with cancer.
